HC Wainwright reiterated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research report report published on Tuesday, TipRanks reports. They currently have a $43.00 price target on the stock.
ALLO has been the subject of several other research reports. Raymond James raised Allogene Therapeutics from a market perform rating to an outperform rating and set a $36.00 price target for the company in a report on Thursday, September 23rd. Bank of America lowered their price target on Allogene Therapeutics from $41.00 to $32.00 and set a buy rating for the company in a report on Friday, October 8th. JMP Securities reissued a buy rating and issued a $27.00 price target on shares of Allogene Therapeutics in a report on Friday, December 17th. William Blair reissued a buy rating on shares of Allogene Therapeutics in a report on Friday, October 8th. Finally, Oppenheimer lowered their price target on Allogene Therapeutics from $44.00 to $40.00 and set an outperform rating for the company in a report on Friday, October 8th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $35.40.
ALLO opened at $13.28 on Tuesday. The business’s 50-day moving average is $16.53 and its two-hundred day moving average is $20.27. Allogene Therapeutics has a 1 year low of $11.54 and a 1 year high of $39.12. The firm has a market capitalization of $1.89 billion, a PE ratio of -7.06 and a beta of 0.71.
In other news, Director Arie Belldegrun bought 155,039 shares of the firm’s stock in a transaction that occurred on Wednesday, January 12th. The stock was purchased at an average price of $12.60 per share, with a total value of $1,953,491.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 26.30% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Moors & Cabot Inc. acquired a new position in Allogene Therapeutics in the third quarter valued at approximately $241,000. Bank of New York Mellon Corp lifted its holdings in Allogene Therapeutics by 12.9% in the third quarter. Bank of New York Mellon Corp now owns 318,805 shares of the company’s stock valued at $8,193,000 after acquiring an additional 36,468 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in Allogene Therapeutics by 485.8% in the third quarter. BNP Paribas Arbitrage SA now owns 15,441 shares of the company’s stock valued at $397,000 after acquiring an additional 12,805 shares during the period. Janus Henderson Group PLC acquired a new position in Allogene Therapeutics in the third quarter valued at approximately $200,000. Finally, Thrivent Financial for Lutherans lifted its holdings in Allogene Therapeutics by 31.0% in the third quarter. Thrivent Financial for Lutherans now owns 54,179 shares of the company’s stock valued at $1,392,000 after acquiring an additional 12,824 shares during the period. 76.34% of the stock is owned by institutional investors.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
Featured Article: Beige Book
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.